Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.
Pembrolizumab Did Not Improve PFS or OS Compared With Paclitaxel in Relapsed Gastric or Gastroesophageal Junction CancerJune 27, 2018
Results from the KEYNOTE-061 were presented at ESMO World GI 2018.
A recent trial evaluated the safety and efficacy of a DC vaccine combined with salvage chemotherapy.
XP-treated patients with metastatic gastric cancer who had tumors expressing UCK2 and OPRT above a specific threshold survived longer than patients with lower levels of these biomarkers.
Researchers assigned patients with various types of relapsed/refractory cancer to receive escalating doses of JTX-2011 alone or plus nivolumab.
Researchers randomly assigned 1204 patients with gastric adenocarcinoma to undergo omentectomy only or bursectomy.
Researchers randomly assigned 788 patients to receive postoperative chemotherapy or chemoradiotherapy.
Researchers identified 4 classifier genes relevant to gastric cancer in 307 patients in an internal cohort.
Researchers are investigating the efficacy of surgical resection plus HIPEC for improving survival outcomes among patients with gastric cancer.
Researchers are evaluating the safety and efficacy of additional chemotherapy and radiation, alone or with surgery, among patients with esophageal or gastric cancer.
Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRS only.
Researchers are evaluating the feasibility and safety of adjuvant HIPEC in patients with locally advanced gastric cancer.
In 2017, new treatment approaches for patients with esophagogastric cancer have been investigated, including novel neoadjuvant regimens and immunotherapies.
Researchers are evaluating the safety and efficacy of FOLFOX plus nab-paclitaxel as a first-line therapy for patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.
Researchers are evaluating the safety and efficacy of PLX9486, a TKI of c-Kit, in combination with pexidartinib (PLX3397) and sunitinib among patients with GIST.
Researchers are investigating the efficacy of pembrolizumab immunotherapy plus chemotherapy as perioperative treatment for patients with gastric cancer or adenocarcinoma of the gastroesophageal junction.
Pembrolizumab monotherapy showed clinical efficacy in patients with advanced gastric cancer.
Perioperative FLOT significantly improved PFS and OS among patients with resectable gastric cancers compared with standard ECF/ECX.
Neoadjuvant FLOT followed by surgery improves outcomes among patients with gastric or gastroesophageal junction cancer.
For this phase 2 trial, researchers are evaluating the efficacy and safety of andecaliximab (GS-5745) and nivolumab vs nivolumab alone.
Patients with operable gastroesophageal cancer with high microsatellite instability did not derive benefit from perioperative chemotherapy.
GEMOX post-surgery adjuvant therapy does not improve relapse-free survival (RFS) among patients with biliary tract cancer.
Bursectomy can be safely performed without increasing the risk of morbidity or mortality among patients with cT3 or cT4 gastric cancer.
The addition of everolimus to paclitaxel did not significantly improve overall response rate, progression-free survival, or overall survival.
For patients with advanced gastric cancer, second-line treatment with ramucirumab is safe and efficacious regardless of age.
Among patients with malignant gastric outlet obstruction caused by gastric cancer, surgical palliation was effective for maintaining patient quality of life.
Omitting surgery and using a watch-and-wait approach does not compromise outcomes for selected patients with advanced rectal cancer.
The FDA has accepted Mylan's Biologics License Application (BLA) for MYL-1401O.
Nivolumab (Opdivo) improved overall survival compared with placebo among patients with unresectable advanced or recurrent gastric cancer.
Mylan has submitted a biologics license application (BLA) for MYL-1401O, a proposed biosimilar trastuzumab, to the FDA.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML